Cancer is a leading cause of morbidity and mortality around the world. According to data from the World Health Organization, 14 million new cases were detected in 2012 and more than eight million individuals died from a malignant tumor. Today, the main challenge faced by oncology is the therapeutic approach to metastasis, a problem known for decades, which is still the top cause of mortality within this wide range of diseases.
The presence of epithelial cells in the bloodstream of a woman with metastatic breast cancer was discovered by T.R. Ashworth more than 150 years ago. His discovery would make it possible to determine, decades later, the existence of circulating tumor cells to monitor the evolution and progression of cancer.
Author: BD Biosciences
BD Biosciences Research Grants –a program open to scientists and R&D labs in the US and selected European countries only- aim to reward and enable important research by providing vital funding to scientists pursuing innovative experiments that advance the scientific understanding of disease. This ongoing program includes grants for immunology and cancer research, totaling $240,000 annually in BD Biosciences research reagents –it does not cover funding for instrumentation-.
Seven years ago, the launch of the International Cancer Genome Consortium (ICGC) ushered in a new era in the understanding of cancer, with the goal of improving clinical diagnosis and treatment of patients.
One in two people in the UK will be diagnosed with cancer during their lifetime. These findings, published by Cancer Research UK, can be extrapolated to any European country given the progressive ageing of the population. In this context, it will be essential to have new methods for the early diagnosis of cancer with the aim of improving the effectiveness of treatments.
Almost 150 years ago, T.R. Ashworth first described the presence of epithelial cells in the blood of a woman with metastatic breast cancer, which were very similar in appearance to her primary tumour cells.